Patent Outcomes Support Plant Doctor's IPO Process, Attracting Attention
Plant Doctor's main board IPO application has been approved, and its deep cooperation model with research institutions has become an important guarantee for continuously improving research capabilities and injecting strong momentum into performance growth. From 2022 to 2024, the company's operating income grew steadily, reaching RMB 211,719,180, RMB 215,108,840, and RMB 215,571,710, respectively; net profit attributable to shareholders increased from RMB 15,803,930 to RMB 24,300,010, with an average compound annual growth rate of 24.00%. This steady performance is inseparable from the research development system.
Source: Plant Doctor's prospectus
Plant Doctor has broken away from the single-enterprise research model and actively collaborated with top research institutions. Among them is the Plant Doctor Research Center jointly established with the Kunming Institute of Botany, Chinese Academy of Sciences. This center serves as a model for the integration of production, education, and research. The center leverages the botanical research advantages of the Kunming Institute to conduct systematic studies on the active components of high-altitude plants, providing a solid scientific basis for product development. This cooperation is not just about technical transfer, but rather involves building joint research teams, sharing research resources, and forming a complete chain from basic research to application and product landing.
In addition to this, the company has collaborated with Jiangnan University to establish a China-based cosmetics raw materials research base, focusing on innovation in raw materials. Jiangnan University's technology accumulation in biotechnology is highly consistent with Plant Doctor's demand for high-altitude plant resources, laying the foundation for the development of "Chinese components".
The results of the production and education cooperation are directly reflected in the output of research and development. As of May 31, 2025, the company has obtained 212 patents, including 59 invention patents. During the reporting period, the company's research and development investments were RMB 7,377,390, RMB 7,587,630, and RMB 6,633,450, respectively, accounting for more than 3% of operating income.
Source: Plant Doctor's prospectus
This cooperation model has brought about technical dividends, continuously driving the upgrading of product matrices and supporting stable growth in performance. In the IPO process, Plant Doctor's experience with production-education cooperation has provided a reference for the cosmetics industry on how to break through technological bottlenecks through research collaboration, and has allowed capital markets to see the sustainability and competitiveness of its research system.
Industry experts have stated that Plant Doctor's deep integration model has broken down barriers between enterprises and research institutions, achieving optimal configuration of technical resources. This model may become the mainstream direction for cosmetics companies to improve their research efficiency.